FGFC1 Selectively Inhibits Erlotinib-Resistant Non-Small Cell Lung Cancer via Elevation of ROS Mediated by the EGFR/PI3K/Akt/mTOR Pathway

Non-small cell lung cancer (NSCLC) is one of the most common malignancies in the world. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have been used as a first-line treatment for patients harboring with EGFR mutations in advanced NSCLC. Nevertheless, the drug resistance aft...

Descripción completa

Detalles Bibliográficos
Autores principales: Yan, Shike, Zhang, Bing, Feng, Jingwen, Wu, Haigang, Duan, Namin, Zhu, Yamin, Zhao, Yueliang, Shen, Shuang, Zhang, Kai, Wu, Wenhui, Liu, Ning
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8807551/
https://www.ncbi.nlm.nih.gov/pubmed/35126111
http://dx.doi.org/10.3389/fphar.2021.764699

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8807551/
https://www.ncbi.nlm.nih.gov/pubmed/35126111
http://dx.doi.org/10.3389/fphar.2021.764699

Ejemplares similares